Coeptis Therapeutics Holdings IncNASDAQ:COEPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3348
- TODAY'S CHANGE (%)0.0128 (3.9752%)
- Bid / Lots0.3200/ 1
- Ask / Lots0.3915/ 50
- Open / Previous Close0.3500 / 0.3220
- Day Range
- 52 Week Range
- Volume52,491
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COEP |
|---|---|---|
| 09:32 ET | 9000 | 0.35 |
| 09:38 ET | 300 | 0.322 |
| 09:39 ET | 300 | 0.3425 |
| 09:43 ET | 100 | 0.3301 |
| 10:08 ET | 6410 | 0.321 |
| 10:26 ET | 295 | 0.3211 |
| 10:48 ET | 2000 | 0.3232 |
| 10:57 ET | 1000 | 0.3381 |
| 11:40 ET | 300 | 0.32799 |
| 12:05 ET | 400 | 0.324599 |
| 12:14 ET | 700 | 0.3246 |
| 12:21 ET | 2273 | 0.3216 |
| 12:30 ET | 900 | 0.322 |
| 12:36 ET | 161 | 0.3251 |
| 01:15 ET | 5273 | 0.3236 |
| 01:55 ET | 1000 | 0.3279 |
| 01:57 ET | 9204 | 0.3281 |
| 02:51 ET | 200 | 0.3286 |
| 03:45 ET | 100 | 0.3291 |
| 03:48 ET | 4000 | 0.329 |
| 03:52 ET | 3952 | 0.3349 |
| 03:56 ET | 700 | 0.3349 |
| 03:59 ET | 935 | 0.3348 |
Apr 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Coeptis Therapeutics Holdings Inc | 11.6M | -0.4x | --- |
Psyence Biomedical Ltd | 11.2M | -19.4x | --- |
Ibio Inc | 14.6M | -0.1x | --- |
Transnational Cannabis Ltd | 10.7M | 0.0x | --- |
Bio Essence Corp | 9.9M | -11.6x | --- |
Processa Pharmaceuticals Inc | 6.9M | -0.2x | --- |
Company Information
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.
Contact Information
- Headquarters
- 105 Bradford Road, Suite 420WEXFORD, PA, United States 15090
- Phone
- 724-934-6467
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.94 |
EPS | $-0.89 |
Book Value | $0.12 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
